Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
NCT03179631 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 6, 2017
- Completion date
- July 25, 2023
- Enrollment
- 360 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.